DE19906979B4 - Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit - Google Patents
Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit Download PDFInfo
- Publication number
- DE19906979B4 DE19906979B4 DE19906979A DE19906979A DE19906979B4 DE 19906979 B4 DE19906979 B4 DE 19906979B4 DE 19906979 A DE19906979 A DE 19906979A DE 19906979 A DE19906979 A DE 19906979A DE 19906979 B4 DE19906979 B4 DE 19906979B4
- Authority
- DE
- Germany
- Prior art keywords
- deoxypeganine
- treatment
- nicotine
- nicotine addiction
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 title claims abstract description 43
- VARHXCYGZKSOOO-UHFFFAOYSA-N Deoxyvasicinone Natural products C1=CC=C2C(=O)N(CCC3)C3=NC2=C1 VARHXCYGZKSOOO-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 206010057852 Nicotine dependence Diseases 0.000 title claims abstract description 11
- 208000025569 Tobacco Use disease Diseases 0.000 title claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 10
- 229960002715 nicotine Drugs 0.000 description 10
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 235000019788 craving Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- KTCXMTWSISEJFZ-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-pyrrolo[2,1-b]quinazolin-10-ium;chloride Chemical compound Cl.C1C2=CC=CC=C2N=C2N1CCC2 KTCXMTWSISEJFZ-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- -1 Flow improver Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 240000005523 Peganum harmala Species 0.000 description 1
- 235000005126 Peganum harmala Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229930013610 lobeline Natural products 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906979A DE19906979B4 (de) | 1999-02-19 | 1999-02-19 | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit |
| DK00905035T DK1150681T3 (da) | 1999-02-19 | 2000-02-08 | Anvendelse af en farmaceutisk sammensætning indeholdende desoxypeganin til behandling af nikotinafhængighed |
| DE50012014T DE50012014D1 (de) | 1999-02-19 | 2000-02-08 | Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit |
| PCT/EP2000/000975 WO2000048445A2 (de) | 1999-02-19 | 2000-02-08 | Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit |
| AT00905035T ATE314850T1 (de) | 1999-02-19 | 2000-02-08 | Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit |
| PT00905035T PT1150681E (pt) | 1999-02-19 | 2000-02-08 | Utilizacao de uma composicao farmaceutica que contem desoxipeganina para o tratamento da dependencia da nicotina |
| JP2000599251A JP4287596B2 (ja) | 1999-02-19 | 2000-02-08 | ニコチン依存症の治療のためのデオキシペガニン含有医薬組成物 |
| EP00905035A EP1150681B1 (de) | 1999-02-19 | 2000-02-08 | Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit |
| KR1020017010491A KR100681631B1 (ko) | 1999-02-19 | 2000-02-08 | 니코틴 의존증 치료를 위한 데옥시페가닌을 포함하는 약학조성물 |
| AU26706/00A AU2670600A (en) | 1999-02-19 | 2000-02-08 | Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence |
| ES00905035T ES2255977T3 (es) | 1999-02-19 | 2000-02-08 | Utilizacion de un compuesto farmaceutico que contiene desoxipeganina para el tratamiento de la dependencia a la nicotina. |
| US09/889,650 US6548510B1 (en) | 1999-02-19 | 2000-02-08 | Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence |
| ARP000100678A AR022621A1 (es) | 1999-02-19 | 2000-02-17 | Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906979A DE19906979B4 (de) | 1999-02-19 | 1999-02-19 | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19906979A1 DE19906979A1 (de) | 2000-08-31 |
| DE19906979B4 true DE19906979B4 (de) | 2004-07-08 |
Family
ID=7898025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19906979A Expired - Fee Related DE19906979B4 (de) | 1999-02-19 | 1999-02-19 | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit |
| DE50012014T Expired - Fee Related DE50012014D1 (de) | 1999-02-19 | 2000-02-08 | Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50012014T Expired - Fee Related DE50012014D1 (de) | 1999-02-19 | 2000-02-08 | Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6548510B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1150681B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4287596B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100681631B1 (cg-RX-API-DMAC7.html) |
| AR (1) | AR022621A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE314850T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2670600A (cg-RX-API-DMAC7.html) |
| DE (2) | DE19906979B4 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1150681T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2255977T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1150681E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000048445A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119863A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen |
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| DE10163667B4 (de) * | 2001-12-21 | 2006-10-26 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung der klinischen Depression |
| DE10304141B4 (de) | 2003-02-03 | 2006-03-09 | Hf Arzneimittelforschung Gmbh | Verfahren zur Herstellung von Chinazolin-Alkaloiden |
| DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
| DE10354893B4 (de) * | 2003-11-24 | 2011-03-10 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen |
| WO2008007163A1 (en) * | 2006-07-11 | 2008-01-17 | Adnan Jathlan Al-Rehaily | Peganine isolated from anisotes trisulcus l. as a smoking deterrent and anorxigenic agent |
| UA112411C2 (uk) | 2010-03-26 | 2016-09-12 | Філіп Морріс Продактс С.А. | Пригнічення подразнення рецепторів при споживанні бездимних тютюнових виробів |
| US8952038B2 (en) | 2010-03-26 | 2015-02-10 | Philip Morris Usa Inc. | Inhibition of undesired sensory effects by the compound camphor |
| US10335378B2 (en) | 2013-03-15 | 2019-07-02 | Altria Client Services Llc | Inhibition of central nervous system effects from smoking and sensory effects from smoking |
| CN104382964B (zh) * | 2014-10-27 | 2017-07-28 | 上海中医药大学 | 一种由骆驼蓬草制备骆驼蓬草总生物碱提取物和骆驼蓬草总黄酮提取物的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3760805A (en) | 1971-01-13 | 1973-09-25 | Alza Corp | Osmotic dispenser with collapsible supply container |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| SU605614A1 (ru) * | 1971-10-20 | 1978-05-05 | Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср | Антихолинэстеразное средство |
| US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| US4137300A (en) | 1976-08-20 | 1979-01-30 | Ciba-Geigy Corporation | Sustained action dosage forms |
| DE3315272C2 (de) | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| DE3629304A1 (de) | 1986-08-28 | 1988-03-24 | Lohmann Gmbh & Co Kg | Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung |
| DE3843239C1 (cg-RX-API-DMAC7.html) | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
| DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
| DE19906975B4 (de) * | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
-
1999
- 1999-02-19 DE DE19906979A patent/DE19906979B4/de not_active Expired - Fee Related
-
2000
- 2000-02-08 AT AT00905035T patent/ATE314850T1/de not_active IP Right Cessation
- 2000-02-08 WO PCT/EP2000/000975 patent/WO2000048445A2/de not_active Ceased
- 2000-02-08 JP JP2000599251A patent/JP4287596B2/ja not_active Expired - Fee Related
- 2000-02-08 PT PT00905035T patent/PT1150681E/pt unknown
- 2000-02-08 KR KR1020017010491A patent/KR100681631B1/ko not_active Expired - Fee Related
- 2000-02-08 AU AU26706/00A patent/AU2670600A/en not_active Abandoned
- 2000-02-08 DE DE50012014T patent/DE50012014D1/de not_active Expired - Fee Related
- 2000-02-08 EP EP00905035A patent/EP1150681B1/de not_active Expired - Lifetime
- 2000-02-08 ES ES00905035T patent/ES2255977T3/es not_active Expired - Lifetime
- 2000-02-08 DK DK00905035T patent/DK1150681T3/da active
- 2000-02-08 US US09/889,650 patent/US6548510B1/en not_active Expired - Fee Related
- 2000-02-17 AR ARP000100678A patent/AR022621A1/es unknown
Non-Patent Citations (1)
| Title |
|---|
| Chem.Abstr. 100:132532t * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010102240A (ko) | 2001-11-15 |
| DE19906979A1 (de) | 2000-08-31 |
| EP1150681B1 (de) | 2006-01-04 |
| AR022621A1 (es) | 2002-09-04 |
| JP2002537232A (ja) | 2002-11-05 |
| DK1150681T3 (da) | 2006-05-22 |
| ATE314850T1 (de) | 2006-02-15 |
| JP4287596B2 (ja) | 2009-07-01 |
| US6548510B1 (en) | 2003-04-15 |
| EP1150681A2 (de) | 2001-11-07 |
| AU2670600A (en) | 2000-09-04 |
| ES2255977T3 (es) | 2006-07-16 |
| WO2000048445A3 (de) | 2001-04-26 |
| DE50012014D1 (de) | 2006-03-30 |
| WO2000048445A2 (de) | 2000-08-24 |
| PT1150681E (pt) | 2006-05-31 |
| KR100681631B1 (ko) | 2007-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0680326B1 (de) | Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit | |
| DE60219478T2 (de) | Orale gabe von 6-hydroxy-oxymorphon als analgetikum | |
| EP0449247B1 (de) | Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus | |
| DE19906979B4 (de) | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit | |
| EP0125634A1 (de) | Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens | |
| EP0214620B1 (de) | Transdermale Applikationsform von Diltiazem | |
| CH662734A5 (de) | Antischnarchmittel. | |
| EP0732926B1 (de) | Pharmazeutische formulierung zur prophylaxe bzw. vorbehandlung einer vergiftung durch phosphororganische cholinesterasehemmer | |
| EP0695182A1 (de) | Systeme zur kontrollierten abgabe von pilocarpin | |
| DE60204694T2 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| EP1154776B1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
| DE4123106A1 (de) | Arzneimittel zur behandlung von entzugssymptomen | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE10338544B4 (de) | Buccale Formulierungen des Galanthamins und deren Anwendungen | |
| DD297557A5 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
| DE10318714B4 (de) | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches | |
| DE19924951B4 (de) | Verwendung von Desoxypeganin zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer | |
| EP0151245A2 (de) | Lorazepam-haltiges Schlafmittel | |
| DE69435084T2 (de) | Die Verwendung von wasserunlöslichem S-Camptothecin mit geschlossenem Lactonring für die Herstellung eines Medikamentes zur Behandlung von Darmkrebs | |
| DE2848938A1 (de) | Pflanzliche arzneimittel zur behandlung von hohem blutdruck | |
| DE10301930A1 (de) | Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNACH, |
|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: HF ARZNEIMITTELFORSCHUNG GMBH, 59368 WERNE, DE |
|
| 8339 | Ceased/non-payment of the annual fee |